Trials / Completed
CompletedNCT05229237
Conbercept for Polypoidal Choroidal Vasculopathy（START Study）
A Multicenter, Observational, Registrie Study of Conbercept in the Treatment of Polypoidal Choroidal Vasculopathy（START Study）
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (actual)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
1. To evaluate the effectiveness of Conbercept for PCV patients. 2. To describe the characteristics of PCV. 3. To describe the adverse events (AE) of Conbercept in the treatment of PCV. 4. Todescirbe the real situation and prognosis of PCV patients in our country.
Detailed description
1. To observe the visual changes in PCV patients receiving Conbercept treatment, so as to evaluate the effectiveness of the treatment. Changes of OCT, ICGA, quality of life and visual function would be observed and evaluated. 2. To observe and describe the characteristics of PCV. 3. To observe and describe the incidence of adverse events (AE) and serious adverse events (SAE) of Conbercept in the treatment of PCV, so as to evaluate the safety of this treatment. 4. To observe and descirbe the real situation and prognosis of PCV patients in our country.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Conbercept | Intravitral injection of Conbercept (0.5 mg/0.05 mL, Chengdu Kanghong Biotech, Inc.) |
Timeline
- Start date
- 2018-05-01
- Primary completion
- 2021-06-05
- Completion
- 2021-12-05
- First posted
- 2022-02-08
- Last updated
- 2022-02-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05229237. Inclusion in this directory is not an endorsement.